**Original Article**

**Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer**

Ken Takahashi¹², Yosuke Seto¹, Koutaroh Okada¹, Shinya Uematsu³, Ken Uchibori³, Mika Tsukahara¹, Tomoko Oh-hara¹, Naoya Fujita⁴, Noriko Yanagitani³, Makoto Nishio³, Kenichi Okubo² & Ryohei Katayama¹

1 Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan
2 Department of Thoracic Surgery, Tokyo Medical and Dental University, Tokyo, Japan
3 Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
4 Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan

**Keywords**
ALK compound mutation; next-generation sequence; non-small cell lung cancer.

**Correspondence**
Ryohei Katayama, Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
Tel: +81-3-3570-0468
Fax: +81-3-3570-0484
Email: ryohei.katayama@jfcr.or.jp

Received: 5 November 2019;
Accepted: 21 December 2019.
doi: 10.1111/1759-7714.13299

**Thoracic Cancer** 11 (2020) 581–587

**Abstract**

**Background:** Anaplastic lymphoma kinase (ALK) fusion genes are found in 3%–5% of non-small cell lung cancers (NSCLCs). ALK inhibitors show a very high response rate to ALK-positive NSCLCs. However, the emergence of acquired resistance is inevitable. In this study, we investigated the drugs for overcoming resistance especially compound mutations after sequential treatment with crizotinib, alectinib, and lorlatinib.

**Method:** Next-generation sequencing (NGS) and Sanger sequencing were performed on a liver biopsy tissue obtained from a clinical case. Ba/F3 cells in which mutant EML4-ALK were overexpressed were prepared, and cell viability assay and immunoblotting were performed to check the sensitivity of five independent ALK inhibitors.

**Results:** I1171S + G1269A double mutation was identified by NGS and Sanger sequencing on a liver biopsy tissue from a patient who relapsed on lorlatinib treatment. Ceritinib and brigatinib—but not other ALK inhibitors—were active against the compound mutations in the cell line model.

**Conclusions:** With the sequential ALK inhibitors treatment, cancer cells accumulate new mutations in addition to mutations acquired previously. The identified compound mutation (I1171S + G1269A) was found to be sensitive to ceritinib and brigatinib, and indeed the patient’s tumor partially responded to ceritinib.

**Key points**
- ALK compound mutation was found in a clinical sample that was resistant to lorlatinib after sequential ALK-tyrosine kinase inhibitor (TKI) treatment.
- Ceritinib and brigatinib are potential overcoming drugs against ALK I1171S + G1269A double mutation.

**Introduction**

Anaplastic lymphoma kinase (ALK) fusion genes are found in 3%–5% of all non-small cell lung cancers (NSCLCs).¹ ALK fusion protein constitutively activates ALK-tyrosine kinase, which increases cell proliferation and becomes cancerous. ALK inhibitors bind to ALK-tyrosine kinase and show a high response rate to ALK-rearranged lung cancer.²
Previously, the first-generation ALK-tyrosine kinase inhibitor (TKI) crizotinib was the standard treatment for newly diagnosed cases of ALK rearrangement NSCLC, because crizotinib showed a response rate of more than 60% and a median progression-free survival (PFS) of approximately one year in clinical trials. However, there was a problem because resistance developed within a couple of years after the treatment started in most of the patients. The major resistance mechanisms to crizotinib included mutations in ALK-tyrosine kinase domains such as L1196M, G1269A, and C1156Y. Alectinib and ceritinib as second-generation ALK-TKIs have been shown to be effective in crizotinib-resistant patients with secondary mutations except for a few resistance mutations such as G1202R. Since the direct comparison of crizotinib and alectinib as first-line therapy in two phase III clinical trials, alectinib has provided significantly longer PFS (more than 34 months in alectinib vs. less than 12 months in crizotinib), and is now widely used as the first-line therapy. Gainor et al. reported that approximately 20%–30% of G1202R mutations occur after treatment with second-generation ALK inhibitors, and the third-generation ALK inhibitor lorlatinib is active against their acquired resistance. Thus, patients with ALK-rearanged NSCLC usually receive the sequential ALK-TKI treatment (previously crizotinib followed by alectinib or ceritinib; currently, alectinib followed by other ALK-TKIs, e.g., ceritinib, lorlatinib, brigatinib [not in Japan], or crizotinib). However, in several reports, diverse compound ALK mutations were identified in lorlatinib-resistant cells or patient samples after these patients had received the sequential ALK-TKI treatments.

The previously reported compound mutations found in patients are F1174V + G1202R, C1156Y + L1198F, E1210K + S1206C, E1210K + D1203N, C1156Y + L1198F, L1171N + L1198F, L1171N + D1203N, L1196M + G1202R, G1202R + G1269A, D1203N + E1210K, G1202R + L1204V + G1269A, D1203N + E1210K + G1269A, R1192P + G1202R, G1202R + G1269A, F1174L + G1202R, T1151M + G1202R, L1196M + G1202R, I1171N + D1203N. Therefore, the search for drugs that can overcome these compound mutations is crucial and urgent. Several reports have shown that some of the lorlatinib-resistant compound mutations became resensitized to first- or second-generation ALK inhibitors (e.g., C1156Y + L1198F became resensitized to crizotinib, and I1171N + L1256F became resensitized to alectinib).

In this report, we describe a case in which I1171S + G1269A compound mutation was acquired after exposure to crizotinib, alectinib, and lorlatinib. As there was no available information about the drug sensitivity of this compound mutation, we prepared cell lines in which EML4-ALK wild-type (WT) and mutants were over-expressed; cell viability assay and immunoblotting analysis were subsequently performed.

**Methods**

**Clinical sample**

The patient provided informed consent for all genetic and cell biological analyses which were performed in accordance with the protocols approved by the Institutional Review Board of the Japanese Foundation for Cancer Research, the Ethics Committee.

**Polymerase chain reaction amplification and Sanger sequencing**

Total RNA was extracted from a specimen of clinical liver metastasis (JFCR 49-2) using Maxwell RSC simplyRNA Tissue Kits (Promega Corp., Madison, WI, USA) according to the manufacturer’s instructions, then reverse-transcribed followed by polymerase chain reaction (PCR) of the ALK kinase domain by nested PCR (first primer: F, AGGCCCT GAGTAAAGCTGAGC, R, CCATATTCTATCGGCAA GCGGT; second primer: F, TCAGTGACCTGAAGGAGA GTTGC, R, TGGTGAATACATCGGTTCCCTGG). PCR products were sequenced using ABI PRISM 3130x Genetic Analyzer (Thermo Fischer Scientific, Waltham, MA, USA).

**Next generation sequencing**

Genomic DNA was extracted with a DNeasy Blood and Tissue Kit (Qiagen, Hilden, Germany). A library was prepared using a HaloPlex custom panel (Agilent Technologies, Inc., Santa Clara, CA, USA), which is designed to detect well-known cancer-associated somatic mutations. The library was then purified and quantified using quantitative PCR, sequenced on Illumina MiSeq Reagent Kit v2 (300 cycles). The sequence reads were aligned to the University of California Santa Cruz hg38 reference genome using HISAT2 (version 2.1.0). Read pairs with a mapping quality of <30 were excluded.

**Cell lines and reagents**

Ba/F3 immortalized murine bone marrow-derived pro-B cells were cultured with Dulbecco’s modified Eagle medium (DMEM) low glucose supplemented with 10% fetal bovine serum (FBS) and kanamycin (250 mg/mL; Meiji Seika Pharma, Tokyo, Japan) and 0.5 ng/mL of interleukin-3 (IL-3). Human kidney embryo cell lines, 293FT cells were cultured in DMEM high glucose with 10% FBS. The cells were infected with lentivirus replicated in 293FT cells by transforming them with pING plasmids.
(Virapower), which express rearranged cDNA regions encoding EML4-ALK variant 1 and either WT or different mutations (I1171S and I1171S + G1269A). Cells were selected with blasticidin (7 μg/mL) for one week. After selection, IL-3 was withdrawn from the culture medium.

Crizotinib (PF-02341066), lorlatinib (PF-06463922), and brigatinib (AP26113) were obtained from Shanghai Biochempartner (Shanghai, China). Alectinib (CH5424802), and ceritinib (LDK-378) was purchased from ActiveBiochem (Hong Kong).

**Antibodies and immunoblotting**

Ba/F3 cells (1 x 10^6) were seeded into 12-well plates and treated with different drugs at different concentrations for three hours. Cells were suspended in lysis buffer containing 0.1 M Tris (pH 7.5), 10% glycerol and 1% sodium dodecyl sulfate (SDS), and boiled at 100°C for five minutes. The protein concentrations were measured with a BCA protein assay Kit (Thermo Fischer Scientific). The lysates were adjusted to 0.9 μg/μL with lysis buffer and 20% volume of the sample buffer containing 0.65 M Tris (pH 6.8), 20% 2-mercaptoethanol, 10% glycerol, 3% SDS, and 0.01% bromophenol blue was added. Next, 10 μg of each sample was electrophoresed using SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotted with the antibodies against total-ALK (#3633S Cell Signaling Technology), phospho-ALK (#3341 Cell Signaling Technology), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (MAB374; Millipore, Billerica, MA, USA).

**Cell viability assays**

The cells were seeded into 96-well plates and treated with serial dilutions of different inhibitors. Each condition was performed in triplicate. For Ba/F3 cells, 2000 cells were plated into 96-well plates and cultured in the medium containing different drugs for 72 hours. After incubation, the cells were incubated with CellTiter-Glo reagent (Promega) for 10 minutes, and luminescence was measured using TriStar LB941 (Berthold Technologies, Bad Wildbad, Germany). GraphPad Prism version 8.0 (GraphPad Software Inc., San Diego, CA, USA) was used to graphically display the data. The half-maximal inhibitory concentration (IC50) values were determined using a nonlinear regression model with a sigmoidal dose response in GraphPad.

**Results**

The patient in this report was a 68-year-old woman who was diagnosed with stage III NSCLC with ALK rearrangement in March 2011. The patient initially underwent left pneumonectomy and was followed-up for one year. After follow-up, her computed tomography (CT) revealed liver and spleen metastasis, therefore chemotherapy was started with cisplatin/pemetrexed/bevacizumab for four cycles. In December 2012, her CT scan revealed recurrence of spleen metastasis, so chemotherapy was discontinued and she was switched to crizotinib therapy. The tumor shrank, but in 2013 liver metastasis appeared, and liver biopsy was performed but failed to include tumor cells (Fig 1a). Alectinib treatment was initiated, but her tumor continued to grow. The patient was then enrolled in a study that included lorlatinib treatment. After two years, her CT scan revealed recurrence of spleen metastasis, so chemotherapy was discontinued and she was switched to crizotinib therapy. The tumor shrank, but in 2013 liver metastasis appeared, and liver biopsy was performed but failed to include tumor cells (Fig 1a). Alectinib treatment was initiated, but her tumor continued to grow. The patient was then enrolled in a study that included lorlatinib treatment. After two years, her CT scan revealed recurrence of spleen metastasis, so chemotherapy was discontinued and she was switched to crizotinib therapy. The tumor shrank, but in 2013 liver metastasis appeared, and liver biopsy was performed but failed to include tumor cells (Fig 1a). Alectinib treatment was initiated, but her tumor continued to grow. The patient was then enrolled in a study that included lorlatinib treatment. After two years, her CT scan revealed another liver metastasis progression, for which the patient underwent a second liver metastasis biopsy (JFCR 49-2) (Fig 1b).

We performed next-generation sequencing (NGS) on the liver biopsy tissue and it showed ALK I1171S and G1269A mutation reads (Fig 2a). Because of the low tumor cellularity in the obtained liver biopsy sample, the number of reads in which mutation is confirmed in NGS represented only about 2% of the reads. In addition to ALK compound mutation, our NGS analysis also revealed the KRAS K117N mutant with a few read counts which is also reported as a resistance mechanism of ALK inhibitor.
We tried to identify ALK mutation from expressing ALK fusion protein in the same sample. Therefore, reverse-transcribed cDNAs from the total RNA of the sample were used to amplify ALK by PCR, and we checked the sequence of the ALK kinase domain using Sanger sequencing. The results showed that 3512 t > g and 3806 g > c mutations in ALK were detected as the major peak (Fig 2b). Based on these facts, it was suggested that JFCR 49-2 acquired resistance to lorlatinib because it has compound mutation I1171S and G1269A in cis. We prepared Ba/F3 cells with overexpressing EML4-ALK WT and I1171S single mutation and I1171S + G1269A double mutation. Of note, EML4-ALK with I1171S + G1269A mutation harboring Ba/F3 cell line grew without IL-3, chr2

c. 3512t>g
p. I1171S

chr12

c. 351a>t
p. K117N

(Fig 3).\textsuperscript{16,17} We tried to identify ALK mutation from expressing ALK fusion protein in the same sample. Therefore, reverse-transcribed cDNAs from the total RNA of the sample were used to amplify ALK by PCR, and we checked the sequence of the ALK kinase domain using Sanger sequencing. The results showed that 3512 t > g and 3806 g > c mutations in ALK were detected as the major peak (Fig 2b). Based on these facts, it was suggested that JFCR 49-2 acquired resistance to lorlatinib because it has compound mutation I1171S and G1269A in cis. We prepared Ba/F3 cells with overexpressing EML4-ALK WT and I1171S single mutation and I1171S + G1269A double mutation. Of note, EML4-ALK with I1171S + G1269A mutation harboring Ba/F3 cell line grew without IL-3,
Figure 4 Ceritinib and brigatinib overcome Ba/F3 cells with I1171S + G1269A double mutation. (a-e) Ba/F3 EML4-ALK WT cells, I1171S cells, and I1171S + G1269A cells were treated with the indicated concentration of crizotinib, alectinib, lorlatinib, ceritinib, and brigatinib. Cell viability was analyzed using the CellTiter-Glo assay. (f) Immunoblotting analysis of phosphor-ALK in EML4-ALK WT cells, I1171S cells, and Ba/F3 I1171S + G1269A cells. The cells were treated with indicated concentrations of ALK-TKIs. ALK phosphorylation in the compound mutation harboring cells was suppressed in ceritinib and brigatinib.
suggesting that this mutant EML4-ALK does not lose oncogenicity.

The cell viability assay using CellTiter-Glo Kit was performed with five different ALK inhibitors: crizotinib, alectinib, ceritinib, lorlatinib, and brigatinib. In crizotinib, alectinib, and lorlatinib treatment, it was shown that the sensitivity for the drugs was decreased in the order of EML4-ALK-WT, I1171S single, and the compound mutation. The IC_{50} values of alectinib, ceritinib and lorlatinib for I1171S + G1269A mutant cells were 412.7, 531.4, and 552.6 nM, respectively (Fig 4a–c). When IC_{50} values of ceritinib, brigatinib, and lorlatinib at lower doses (Fig 4d,e), and these inhibitors are also similarly effective against EML4-ALK-WT and I1171S single mutant-expressing cells. Moreover, immunoblotting analysis showed that ALK phosphorylation was suppressed in brigatinib and ceritinib at lower doses (Fig 4f). From these results, it follows that if I1171S and G1269A compound mutation is observed, the resistance would be overcome with ceritinib or brigatinib.

Indeed, ceritinib at a dose of 750 mg/day was selected for subsequent molecular targeted therapy, and it inhibited liver metastasis progression for four months. However, because of grade 2–3 gastrointestinal symptoms such as anorexia and vomiting, dose reduction was necessary, and eventually treatment was discontinued.

**Discussion**

Since ALK fusion gene positive lung cancer was first reported in 2007,19 various ALK-TKIs have been developed and clinically used in various countries all over the world. Although high response rates of the ALK-TKIs have been reported, acquired resistance mechanisms have also been noted such as gatekeeper mutation, ALK fusion gene amplification, and activation of alternative signaling pathways such as epidermal growth factor receptor (EGFR), c-Kit, and KRAS.19,20 The current treatment strategy is sequential ALK targeted therapy regardless of what mutant was acquired by first-line ALK inhibitor treatment. Resistance against the third-generation ALK-TKI lorlatinib, which is currently the later line of therapy, has been reported in multiple different compound mutations found via mutagenesis screening and clinical samples.7,8 In fact, in one patient, different resistance mutation harboring cells were simultaneously detected. The occurrence of multiple compound mutations is attributed to the diversity of cancer cells in the tumor tissue. In this study, our NGS results showed a few read counts of KRAS K117N mutation in addition to ALK compound mutation. This suggests that various responses to molecular targeted therapy could have occurred, and it also reflects intratumor heterogeneity. Therefore, the treatment strategy of ALK-TKI will become diverse and difficult. Because of the mixed/complex resistant mechanisms, there may be limitations to use different kinds of ALK-TKI. In some instances, chemotherapy plus immune checkpoint inhibitor might be a reasonable alternative.

In this study, NGS analysis was performed using a biopsy specimen of liver metastasis after resistance to lorlatinib treatment, and ALK I1171S and G1269A compound mutation was found. Although the distance between I1171S and G1269A mutations is 98 amino acids, a library for this NGS was prepared from genomic DNA that contains long introns between these two mutations, and even if we used cDNA for detection of these mutations, the length of the sequencing reads is too short (approximately 150 bp) to find these two mutations in the same reads. A different technique such as long-read sequence would be required to confirm if the mutations were in cis or in trans. In our study, we could fortunately confirm that mutations were in cis by amplifying ALK fusion gene from cDNA of the biopsy tissue. But if the option of detecting the mutations from cell-free DNA in blood was considered then it would be impossible to clarify if the distant mutations were in cis or in trans.

No tumor cells were found in the liver metastasis biopsy after crizotinib resistance, so it is unclear which of the mutations I1171S and G1269A was acquired first. In this clinical course, NGS of liquid biopsy was also performed after lorlatinib resistance, and mutations of ALK I1171S and G1269A were independently observed. Liquid biopsy NGS showed that G1269A was approximately twice as many as the I1171S read count. This fact may suggest that I1171S single mutant was first acquired after crizotinib treatment, and sequential ALK inhibitor treatment decreased I1171S single mutation and the acquisition of new G1269A mutation after lorlatinib caused compound mutation. This speculation is consistent with the ineffectiveness of alectinib after crizotinib, as I1171S mutant ALK is known to be resistant to alectinib.

Treatment of ALK rearranged positive lung cancer requires sequential use of first-, second-, and third-generation ALK inhibitors, but the sensitivity of these drugs differs for each resistance, and individualized treatment will be required for patients. Analysis of acquired mutations for each drug and treatment strategies will be essential, and multiple analyses along the clinical course progression similar to that reported in this study might be required promptly for a better prognosis of patients with ALK-rearranged NSCLC.

**Acknowledgments**

We thank all laboratory members especially Dr A. Takemoto, and Dr S. Takagi at Japanese Foundation for Cancer Research.
(JFCR) for fruitful discussions and technical advices for the in vitro experiments. We also thank Dr Siew-Kee Low for the NGS analysis using blood sample.

Disclosure

R. Katayama reports research grants from Chugai, TAKEDA, TOPPAN Printing, FUJIFILM, Daichi-sankyo, Taiho, and lecture fees from Pfizer, outside the submitted work. M. Nishio reports grants and personal fees from Ono Pharmaceutical, grants and personal fees from Bristol Myers Squibb, grants and personal fees from Pfizer, grants and personal fees from Chugai Pharmaceutical, grants and personal fees from Eli Lilly, grants and personal fees from Taiho Pharmaceutical, grants and personal fees from Boehringer-Ingelheim, grants and personal fees from MSD, grants and personal fees from Novartis, personal fees from Sankyo Healthcare, personal fees from Taiho Pharmaceutical, personal fees from Merck Serono, grants from Astellas, outside the submitted work. N. Fujita reports grants from Api Co., Ltd., outside the submitted work. There are no further disclosures related to this work.

References

1 Kohno T, Nakao T, Tsuta K et al. Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. Transl Lung Cancer Res 2015; 4 (2): 156–64.
2 Hallberg B, Palmer RH. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer 2013; 13 (10): 685–700.
3 Solomon BJ, Mok T, Kim DW et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014; 371 (23): 2167–77.
4 Gainor JF, Dardaei L, Yoda S et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov 2016; 6 (10): 1118–33.
5 Peters S, Camidge DR, Shaw AT et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 2017; 377 (9): 829–38.
6 Hida T, Nokihara H, Kondo M et al. Alectinib versus crizotinib in patients with ALK-positive non-small lung cancer (J-ALEx): An open-label, randomised phase 3 trial. Lancet 2017; 390 (10089): 29–39.
7 Shaw AT, Friboulet L, Leshchiner I et al. Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. N Engl J Med 2016; 374 (1): 54–61.
8 Yoda S, Lin JJ, Lawrence MS et al. Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer. Cancer Discov 2018; 8 (6): 714–29.
9 Okada K, Araki M, Sakashita T et al. Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance. EBioMedicine 2019; 41: 105–19.
10 Ignatius Ou SH, Azada M, Hsiang DJ et al. Next-generation sequencing reveals a novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. J Thorac Oncol 2014; 9 (4): 549–53.
11 Bagliivo S, Ricciuti B, Ladovini V et al. Dramatic response to lorlatinib in a heavily pretreated lung adenocarcinoma patient harboring G1202R mutation and a synchronous novel R1192P ALK point mutation. J Thorac Oncol 2018; 13 (8): e145–e7.
12 Kougioumtzi A, Ntellas P, Papadopoulou E, Nasioulas G, Kampiltsas E, Pentheroudakis G. Molecular findings reveal possible resistance mechanisms in a patient with ALK-rearranged lung cancer: A case report and literature review. ESMO Open 2019; 4 (5): e000561.
13 Pailler E, Faugeron X, Oulhen M et al. Acquired resistance mutations to ALK inhibitors identified by single circulating tumor cell sequencing in ALK-rearranged non-small-cell lung cancer. Clin Cancer Res 2019; 25 (22): 6671–82.
14 Dagogo-Jack I, Rooney M, Lin JJ et al. Treatment with next-generation ALK inhibitors fuels plasma ALK mutation diversity. Clin Cancer Res 2019; 25 (22): 6662–70.
15 Katayama R, Gong B, Togashi N et al. The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models. Nat Commun 2019; 10 (1): 3604.
16 Stolze B, Reinhart S, Bullinger L, Frohling S, Scholl C. Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines. Sci Rep 2015; 5: 8535.
17 Su F, Bradley WD, Wang Q et al. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Cancer Res 2012; 72 (4): 969–78.
18 Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448 (7153): 561–6.
19 Doebele RC, Pilling AB, Aisner DL et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Cancer Res 2012; 18 (5): 1472–82.
20 Katayama R, Shaw AT, Khan TM et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med 2012; 4 (120): 120ra17.